QRG Capital Management Inc. Buys 12,755 Shares of Eli Lilly and Company $LLY

QRG Capital Management Inc. raised its stake in Eli Lilly and Company (NYSE:LLY) by 9.6% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 146,305 shares of the company’s stock after purchasing an additional 12,755 shares during the period. Eli Lilly and Company accounts for approximately 1.3% of QRG Capital Management Inc.’s investment portfolio, making the stock its 12th largest holding. QRG Capital Management Inc.’s holdings in Eli Lilly and Company were worth $175,483,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in LLY. BlackRock Inc. grew its position in shares of Eli Lilly and Company by 1.6% in the 2nd quarter. BlackRock Inc. now owns 67,540,400 shares of the company’s stock worth $81,009,981,000 after buying an additional 1,046,558 shares during the last quarter. State Street Corp raised its stake in shares of Eli Lilly and Company by 1.7% during the 2nd quarter. State Street Corp now owns 36,215,754 shares of the company’s stock worth $43,438,262,000 after acquiring an additional 605,752 shares in the last quarter. Capital World Investors lifted its position in Eli Lilly and Company by 0.4% during the fourth quarter. Capital World Investors now owns 15,031,750 shares of the company’s stock valued at $16,154,619,000 after acquiring an additional 61,851 shares during the last quarter. Bank of America Corp DE purchased a new stake in Eli Lilly and Company during the second quarter valued at approximately $13,522,666,000. Finally, Norges Bank acquired a new stake in Eli Lilly and Company in the fourth quarter valued at approximately $12,976,634,000. 82.53% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Eli Lilly and Company news, EVP Anat Hakim sold 5,000 shares of Eli Lilly and Company stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the completion of the sale, the executive vice president owned 11,875 shares of the company’s stock, valued at approximately $14,131,250. The trade was a 29.63% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald Zakrowski sold 2,000 shares of the business’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the sale, the chief accounting officer owned 1,526 shares in the company, valued at approximately $1,808,325.26. The trade was a 56.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 13,500 shares of company stock worth $15,958,170 in the last 90 days. Insiders own 0.14% of the company’s stock.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: CEO Dave Ricks said Lilly is capturing about 70% of new senior GLP-1 patients following Medicare coverage expansion, while oral GLP-1 drug Foundayo accounts for roughly one-third of new oral-treatment starts. The comments reinforce Lilly’s commercial leadership and suggest that expanded insurance coverage could materially enlarge the addressable market. Lilly CEO discusses Medicare GLP-1 market share
• Positive Sentiment: Lilly broke ground on a $6.5 billion Houston manufacturing facility that will produce active ingredients for Foundayo and other medicines. The investment supports the company’s planned oral GLP-1 rollout, strengthens domestic supply, and is expected to create more than 600 jobs, although the benefits will take time to materialize. Lilly Houston manufacturing facility
• Positive Sentiment: Investors remain bullish on Lilly’s long-term growth. Home Depot co-founder Ken Langone said the shares could reach $2,000 within three to four years, reflecting confidence in the company’s obesity portfolio and broader pipeline. Ken Langone bullish on Lilly
• Neutral Sentiment: Lilly received full FDA approval for Inluriyo in combination with Verzenio for advanced ESR1-mutated breast cancer, adding support to its oncology franchise. The approval is strategically positive but likely less important to near-term valuation than the obesity business. Inluriyo FDA approval
• Negative Sentiment: Viking Therapeutics reported data indicating its VK2735 obesity drug preserved most weight loss with every-other-week or monthly dosing. The result drove strong interest in a potential competitor to Zepbound, raising concerns about future pricing, adherence, and market-share pressure for Lilly, although Viking still needs Phase 3 results and regulatory approval. Viking obesity drug maintenance data
• Negative Sentiment: Novo Nordisk’s CagriSema also produced favorable late-stage weight-loss data in a diabetes study, keeping competitive pressure high. Lilly’s $6.5 billion facility further increases near-term capital spending, which may temper enthusiasm despite strong long-term demand.

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock traded down $16.45 during mid-day trading on Wednesday, reaching $1,153.69. 2,153,958 shares of the company traded hands, compared to its average volume of 3,016,686. The company has a debt-to-equity ratio of 1.41, a current ratio of 1.35 and a quick ratio of 1.00. Eli Lilly and Company has a fifty-two week low of $712.05 and a fifty-two week high of $1,292.65. The company has a market capitalization of $1.09 trillion, a price-to-earnings ratio of 38.71, a price-to-earnings-growth ratio of 1.44 and a beta of 0.50. The firm’s fifty day moving average is $1,176.84 and its two-hundred day moving average is $1,079.50.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, topping the consensus estimate of $6.40 by $1.98. The business had revenue of $22.97 billion during the quarter, compared to the consensus estimate of $20.82 billion. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The business’s revenue for the quarter was up 47.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. On average, equities research analysts expect that Eli Lilly and Company will post 36.54 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on LLY. JPMorgan Chase & Co. lifted their price target on shares of Eli Lilly and Company from $1,300.00 to $1,400.00 and gave the stock an “overweight” rating in a report on Tuesday, July 7th. Wells Fargo & Company raised their price objective on Eli Lilly and Company from $1,280.00 to $1,330.00 and gave the stock an “overweight” rating in a research report on Thursday, August 6th. HSBC raised their price objective on Eli Lilly and Company from $850.00 to $940.00 and gave the stock a “reduce” rating in a research report on Thursday, September 10th. BMO Capital Markets reaffirmed an “outperform” rating on shares of Eli Lilly and Company in a research report on Wednesday, September 9th. Finally, Berenberg Bank set a $1,400.00 price target on Eli Lilly and Company and gave the company a “buy” rating in a research note on Tuesday, September 15th. One analyst has rated the stock with a Strong Buy rating, twenty-five have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $1,305.25.

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its portfolio includes treatments for diabetes and obesity, oncology, immunology, neuroscience, cardiovascular disease and other areas of significant unmet medical need.

The company’s products include Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, and insulin products such as Humalog. Lilly also markets Verzenio for certain breast cancers and Kisunla for the treatment of early symptomatic Alzheimer’s disease.